logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Polyarticular Juvenile Idiopathic Arthritis Rheumatoid Factor Negative

    FiltersReset Filters
    10 results

    • amjevita

      (adalimumab-atto)
      Amgen Inc
      Usage: AMJEVITA is indicated for treating various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients, depending on the specific condition.

    • cyltezo

      (adalimumab-adbm)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients aged 2 and older.

    • enbrel

      (etanercept)
      Immunex Corporation
      Usage: Enbrel is indicated for reducing symptoms and structural damage in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, chronic moderate to severe plaque psoriasis, and active juvenile psoriatic arthritis in patients 2 years and older. It may be used alone or with methotrexate.

    • hadlima

      (adalimumab-bwwd)
      Organon LLC
      Usage: HADLIMA is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and/or pediatric patients. It can be used alone or with other therapies.

    • kevzara

      (sarilumab)
      sanofi-aventis U.S. LLC
      Usage: KEVZARA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis and polymyalgia rheumatica who have had inadequate responses to DMARDs or corticosteroids. It is also indicated for active polyarticular juvenile idiopathic arthritis in patients weighing 63 kg or more.

    • naproxen

      (Naproxen)
      Glenmark Pharmaceuticals Inc., USA
      Usage: Naproxen tablets and naproxen sodium tablets are indicated for the relief of symptoms related to rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis. They also treat tendonitis, bursitis, acute gout, manage pain, and alleviate primary dysmenorrhea.

    • orencia

      (abatacept)
      E.R. Squibb & Sons, L.L.C.
      Usage: ORENCIA® is indicated for treating moderately to severely active rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis in patients aged 2 and older, active psoriatic arthritis in patients 2 years and older, and for prophylaxis of acute graft versus host disease in hematopoietic stem cell transplant recipients.

    • otrexup

      (methotrexate)
      Antares Pharma, Inc.
      Usage: Otrexup is indicated for managing severe, active rheumatoid arthritis in adults and children with polyarticular juvenile idiopathic arthritis, as well as for the symptomatic control of severe psoriasis in adults unresponsive to other treatments. It is not for neoplastic diseases.

    • simponi aria

      (golimumab)
      Janssen Biotech, Inc.
      Usage: SIMPONI ARIA is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults, active psoriatic arthritis in patients aged 2 and older, active ankylosing spondylitis in adults, and active polyarticular juvenile idiopathic arthritis in patients aged 2 and older.

    • yusimry

      (adalimumab-aqvh)
      Coherus BioSciences Inc
      Usage: YUSIMRY is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis. It helps reduce symptoms, improve function, and inhibit structural damage in these conditions.